Reference standards are used to calibrate similar assay systems against an international reference protocol and to provide a template for the preparation of secondary and/or working standards. Three reference standards are recommended for the indirect enzyme-linked immunosorbent assay: a strong positive standard, a weak positive standard and a negative serum standard. The negative standard should be derived from a single serum or from a serum pool which exhibits typical background activity in the reference protocol. The strong and weak positive standards should be derived from a single serum or from a serum pool which typifies the humoral response (antibody) to natural infection. Suitable candidates for the positive reference standards should exhibit dose/response curves in the mid-range of antibody activity. The strong and weak positive standards should each be prepared from a one-time dilution in the negative standard, to yield antibody activities which are defined by specific points on the linear portion of the dose/response curve. The strong positive standard should represent an antibody activity (absorbance value) midway between the upper and central points and the weak positive standard should represent an antibody activity midway between the central and lower points of the linear portion of the curve. Owing to inherent differences among assay systems, antibody activities should be expressed in relative rather than in absolute terms. It is recommended that the antibody activity of the strong positive standard should denote 100% positivity. The activities of the weak positive and negative standards should then be expressed as relative percentages. Every set of international reference standards should be accompanied by an information sheet which includes, among other things, a plot of the dose/response curve and an indication of the dilutions used to prepare the standards.
Introduction
International reference standards are necessary to ensure that a given antibody detection system is capable of measuring antibody activity to a specified level of diagnostic sensitivity.
Diagnostic sensitivity relates to the risk of a false negative reaction occurring in an antibody assay when an animal is, in fact, infected (4) . This is especially important when an assay is being used to qualify animals or animal products for international trade. The term International reference standard' is synonymous with 'primary reference standard'. This term represents the recognised standard by which other standards are defined and by which other tests are calibrated against the reference protocol. Other such standards include secondary reference standards, which often represent national standards, and working standards, which are routinely üsed at the diagnostic laboratory level as assay controls (1,2, 5).
In this paper, a working example is presented for the selection 
Materials and methods

Indirect enzyme-linked immunosorbent assay
The indirect ELISA kit for the detection of bovine serum antibody to Brucella abortus was produced by the Animal Production Unit of the Laboratories Division of the IAEA. A mouse monoclonal anti-bovine immunoglobulin G10 (IgG1) (designated M-23) conjugated with horseradish peroxidase is used in this assay. The conjugate (batch M23921019B) was also supplied by K. Nielsen in freeze-dried aliquots, which were reconstituted with 2.0 ml of 50% glycerol/water, sub-aliquotted and stored at -20°C for future use. The above reconstitution represented a 1/10 dilution of the original product.
Standard test procedures were used throughout these experiments and are briefly described below:
a) The SLPS antigen was diluted to a concentration of 1.0 µg/ml in fresh, 0.05 M carbonate/bicarbonate coating buffer, pH 9.6. One hundred µl volumes were added to all 96 wells of flat-bottomed, polystyrene microplates (+Polysorp Immuno Plates, Nunc, Denmark). After sealing the plates, antigen adsorption to the wells was allowed to proceed for 18-24 hours at +4°C.
b)
Immediately prior to use, the antigen-coated plates were washed three times with a 1/5 dilution of phosphate buffered saline (PBS) (described below), containing 0.05% (v/v) Tween 20. c) Test sera and control sera were diluted in 0.01 M PBS diluent buffer, pH 7.4, containing 0.05% Tween 20. All test sera and controls were applied in 100 µl volumes. For quality control purposes, four replicates of the following were tested on at least one microplate in any given run: a strong antibody positive (C++) serum control, a weak antibody positive (C+) serum control and an antibody negative (C-) serum control.
The three serum controls were tested at a standard dilution of 1/200. A fourth control of diluent only (no serum) was included as a conjugate control. After sealing the plates, the sera were allowed to react for 1 hour at +37°C with constant plate shaking. d) Immediately after incubation, the plates were washed as described above.
e) The conjugate was optimally diluted to a final working dilution of 1/10,000 in the above PBS diluent buffer. This optimal dilution was defined as that dilution of conjugate which consistently resulted in absorbance values between 1.0 and 1.2 units, when reacted with the C++ control under the standard assay conditions described in this protocol. One hundred µl volumes of optimally diluted conjugate were added to all 96 wells of each microplate. After sealing the plates, the conjugate was allowed to react for 1 hour at +37°C with constant plate shaking. f) Immediately after incubation, the plates were washed as described above.
g) The substrate solution was prepared immediately before use and consisted of 4.4 mM H 2 0 2 and 3.6 mM 2,2'-azino- h) The enzymatic reaction was stopped by the addition of 100 pi volumes of a 4% solution of sodium dodecyl sulfate to all wells of the microplate.
i) Colour development (absorbance) was measured using a microplate photometer with a 405 ran interference filter.
Candidate reference sera
Sera from healthy cattle were obtained from the Veterinary University of Vienna. These cattle were from a herd with no previous history of brucellosis or vaccination. After screening individual candidate sera in the ELISA for abnormal background activity and/or evidence of cross-reacting antibody, 29 sera were pooled. The pool was retested and used as the negative reference standard in this exercise.
Twelve sera from B. abortus-infected cattle were used in this example: seven sera were received from the Veterinary Research Laboratory, Cork, Ireland; three sera from the Central Veterinary Laboratory (Weybridge), New Haw, Addlestone, United Kingdom, and two sera from the Animal Diseases Research Institute, Nepean, Canada. These positive sera are coded from Pl to P12 in this study.
All of the positive sera were reactive in the serum agglutination test, with titres ranging from 1/80 to 1/2,560; all gave positive results in the complement fixation test, with titres ranging from 1/20 to 1/2,560 and all gave positive results in the indirect ELISA, with titres ranging from 1/400 to 1/51,200. These preceding results were reported by the donating laboratories, based on their own reagents and protocols.
Positive serum titrations -initial characterisation
Prior to testing, each of the 12 positive candidate sera was serially diluted using the negative reference serum as the primary diluent. The positive titration series consisted of neat serum plus 11 two-fold dilutions, ranging from 1/2 to 1/2,048 in the negative reference. At the time of testing, each sample in the series was further diluted 1/200 in PBS diluent buffer. Each dilution was tested in quadruplicate. These titrations were repeated on a different day with a fresh set of dilutions.
The mean absorbance values of the quadruplicates from each run were assessed in correlation analysis as a measure of assay repeatability.
Mean absorbance values were recalculated from all eight replicates of each dilution, i.e., from both runs combined, for each of the 12 individual candidate sera. These means were used to establish individual dose/response profiles. Two methods were used for comparing these candidate sera. The first was based on a comparison of the individual dose/response profiles with the grand mean profile ±1 standard deviation calculated from all 12 candidate sera combined. The second was based on a comparison of correlation coefficients after regression of individual profiles with the grand mean dose/response profile. To illustrate the effect of high-and low-range antibody activities in the above comparisons, those sera demonstrating dose/response profiles outside the +1 standard deviation limits were discarded, a second grand mean and standard deviation were calculated from the remaining sera, and individual dose/response profiles and correlation coefficients were again compared.
Using the same criterion as above, a third grand mean and standard deviation were calculated for the remaining sera, and individual dose/response profiles and correlation coefficients were again compared. 
Serum titrations -final characterisation
Results
The mean absorbance values for run 1 and run 2 for. the 12 positive serum candidates were subjected to correlation analysis. The data for the two runs demonstrated a correlation of 0.992 with a slope of 1.001 and an intercept of 0.012. Based on this high degree of repeatability, the data from both runs were combined for further comparisons.
The mean dose/response profiles for all 12 candidate positive sera are shown in Figure 1 . The white beaded line flanked by the shaded areas represents the grand mean ±1 standard Table I . Four sera demonstrated coefficients of correlation which were < 0.950. These sera (P2, P3, P8 and P12) corresponded with those identified above as being outside the ±1 standard deviation limits.
The mean dose/response profiles for the remaining 8 candidate sera are shown in Figure 2 
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Fig. 2 Mean dose/response profiles for remaining 8 positive serum candidates
The white beaded line flanked by shaded areas represents the grand mean (number = 8) dose/response profile ±1 standard deviation. Based on these data, four additional candidate sera (P6, P7, P9 and P11 ) were eliminated from further analysis 1,2 and 3 
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Serum dilution (1/n log 2 X 200) The white beaded line flanked by shaded areas represents the grand mean (number=4) dose/response profile ±1 standard deviation. Based on these data, one serum (PI) was arbitrarily chosen for further characterisation
The mean dose/response profiles for the last remaining 4 candidate sera are shown in Figure 3 . The white beaded line flanked by the shaded areas represents the grand mean ±1 standard deviation of the 4 sera. Three of the sera (Pl, P4 and P10) demonstrated dose/response profiles which were within the narrow confines of the ±1 standard deviation limits. One serum (P5) was just outside the upper limit.
The coefficients of correlation for these 4 sera derived from régression, analysis against the third grand mean (n = 4) dose/response profile are shown in Table I . The one serum (P5) which was just outside the limit demonstrated a correlation coefficient of 0.994, while the other 3 sera continued to demonstrate coefficients > 0.995. P1 was chosen for further use. 
Discussion
The first step in the process of creating reference standards is trie selection of the negative serum or serum pool. Only sera from animals which have never been exposed to or vaccinated against the organism in question should be considered. Individual sera should be screened to ensure that there is no evidence of cross-reacting antibodies or other nonspecific factors which may interfere with the test. Negative sera will demonstrate a range (albeit narrow) of background activity in the ELISA and, if a single serum from one individual is to be used, then it would be prudent to select a serum which demonstrates typical background activity. The term 'typical' is difficult to define, other than that the background activity observed should be representative of the majority of negative sera. For an international standard, it might be best to use a pool of negative sera in order to minimise any single factor peculiar to an individual animal, which may contribute unexpectedly to elevated or depressed background activity in other laboratories. This may also make the negative sera easier to duplicate when other laboratories are preparing secondary reference standards against the primary standard.
The second step in the process is the selection of the positive serum to be used in making the strong and weak positive reference standards. Again, it is recommended that only sera from animais which exhibit a typical humoral (antibody) response should be considered. The dose/response profiles in Figure 1 illustrate just how diverse that antibody response can be. Once more, the term 'typical' is difficult to define because there are a number of factors related to the interaction of the host and the organism which contribute to the diversity observed in the antibody response. If experimental infection or immunisation is used to elicit an antibody response, care should be taken to ensure that the response does mimic what would be expected in the natural course of infection.
Otherwise, the profile may be 'atypical' and impossible to reproduce when preparing subsequent reference standards.
In It could be argued that any one of these 12 sera could be used to prepare strong and weak positive reference standards and that it is not necessary to choose mid-range titred sera. However, the purpose of these standards is to facilitate the calibration of other indirect ELISAs and to act as a template for the preparation of secondary and/or working standards in individual countries. Calibration should harmonise the diagnostic performance characteristics of tests which are similar but not necessarily identical. The reference protocol, if such a protocol has been developed and standardised properly, should detect a wide range of antibody activity and demonstrate diagnostic performance characteristics suitable for international trade. That is not to say that other ELISAs of greater diagnostic specificity or of greater diagnostic sensitivity do not exist. It does imply that such ELISAs may not be suitable for international trade unless they can match or exceed the diagnostic specificity and, most importantly, the diagnostic sensitivity attributes of the reference protocol.
Therefore, both the dose/response profile and the dilutions selected for the strong and weak positive reference standards will help to define the detectable range of antibody activity expected of the test. This will give individual laboratories a reasonable idea as to whether the analytical and, by inference, the diagnostic performance of their assays is comparable with the reference protocol. By including the dose/response profile with each set of reference standards, this process will also give these laboratories better guidelines for any assay modification that may be required, and for the selection of secondary (national) or working standards.
Choosing a mid-range serum also makes it much easier to define the linear portion of the dose/response profile because of the sigmoidal shape of the profile. This in turn removes the subjectivity from defining the points on the curve which are to be selected for the strong positive and weak positive reference As there are many factors (above) which contribute to the operational differences observed between assays and laboratories, it is not possible to ascribe a single, specific positive/negative cut-off or threshold to all assays. Even subde protocol or reagent differences may result in thresholds which vary by several percentage points. If an assay has been calibrated properly against a set of international reference standards, and if working standards have been properly integrated into internal quality control, then the weak positive standard should be unequivocally positive and the negative standard unequivocally negative. However, assay performance and laboratory proficiency should also be assessed, using external check sample panels in an external quality assurance programme. 
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